http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Byeong-Keuk,Kim, Jung-Sun,Park, Junbeom,Ko, Young-Guk,Choi, Donghoon,Jang, Yangsoo,Hong, Myeong-Ki Yonsei University College of Medicine 2012 Yonsei medical journal Vol.53 No.3
<P><B>Purpose</B></P><P>There is a lack of sufficient data in comparison of optical coherence tomographic (OCT) findings between first- and second-generation drug-eluting stents (DES). Compared to first-generation (i.e., sirolimus- or paclitaxel-eluting stents), second-generation DESs (i.e., everolimus- or biolinx-based zotarolimus-eluting stents) might have more favorable neointimal coverage.</P><P><B>Materials and Methods</B></P><P>Follow-up OCT findings of 103 patients (119 lesions) treated with second-generation DESs were compared with those of 139 patients (149 lesions) treated with first-generation DESs. The percentage of uncovered or malapposed struts, calculated as the ratio of uncovered or malapposed struts to total struts in all OCT cross-sections, respectively, was compared between the two groups.</P><P><B>Results</B></P><P>Both DES groups showed similar suppression of neointimal hyperplasia (NIH) on OCT (mean NIH cross-sectional area; second- vs. first-generation=1.1±0.5 versus 1.2±1.0 mm<SUP>2</SUP>, respectively, <I>p</I>=0.547). However, the percentage of uncovered struts of second-generation DESs was significantly smaller than that of first-generation DESs (3.8±4.8% vs.7.5±11.1%, respectively, <I>p</I><0.001). The percentage of malapposed struts was also significantly smaller in second-generation DESs than in first-generation DESs (0.4±1.6% vs.1.4±3.7%, respectively, <I>p</I>=0.005). In addition, intra-stent thrombi were less frequently detected in second-generations DESs than in first-generation DESs (8% vs. 20%, respectively, <I>p</I>=0.004).</P><P><B>Conclusion</B></P><P>This follow-up OCT study showed that second-generation DESs characteristically had greater neointimal coverage than first-generation DESs.</P>
Kim, Young Dae,Song, Dongbeom,Nam, Hyo Suk,Choi, Donghoon,Kim, Jung-Sun,Kim, Byeong-Keuk,Chang, Hyuk-Jae,Choi, Hye-Yeon,Lee, Kijeong,Yoo, Joonsang,Lee, Hye Sun,Nam, Chung Mo,Heo, Ji Hoe Yonsei University, College of Medicine 2017 Yonsei medical journal Vol.58 No.1
<P><B>Purpose</B></P><P>Although asymptomatic coronary artery occlusive disease is common in stroke patients, the long-term advantages of undergoing evaluation for coronary arterial disease using multi-detector coronary computed tomography (MDCT) have not been well established in stroke patients. We compared long-term cardio-cerebrovascular outcomes between patients who underwent MDCT and those who did not.</P><P><B>Materials and Methods</B></P><P>This was a retrospective study in a prospective cohort of consecutive ischemic stroke patients. Of the 3117 patients who were registered between July 2006 and December 2012, MDCT was performed in 1842 patients [MDCT (+) group] and not in 1275 patients [MDCT (−) group]. Occurrences of death, cardiovascular events, and recurrent stroke were compared between the groups using Cox proportional hazards models and propensity score analyses.</P><P><B>Results</B></P><P>During the mean follow-up of 38.0±24.8 months, 486 (15.6%) patients died, recurrent stroke occurred in 297 (9.5%), and cardiovascular events occurred in 60 patients (1.9%). Mean annual risks of death (9.34% vs. 2.47%), cardiovascular events (1.2% vs. 0.29%), and recurrent stroke (4.7% vs. 2.56%) were higher in the MDCT (−) group than in the MDCT (+) group. The Cox proportional hazards model and the five propensity score-adjusted models consistently demonstrated that the MDCT (−) group was at a high risk of cardiovascular events (hazard ratios 3.200, 95% confidence interval 1.172–8.735 in 1:1 propensity matching analysis) as well as death. The MDCT (−) group seemed to also have a higher risk of recurrent stroke.</P><P><B>Conclusion</B></P><P>Acute stroke patients who underwent MDCT experienced fewer deaths, cardiovascular events, and recurrent strokes during follow-up.</P>
Immediate and late outcomes of endovascular therapy for lower extremity arteries in Buerger disease
Kim, Dae-Hoon,Ko, Young-Guk,Ahn, Chul-Min,Shin, Dong-Ho,Kim, Jung-Sun,Kim, Byeong-Keuk,Choi, Donghoon,Hong, Myeong-Ki,Jang, Yangsoo C.V. Mosby Co 2018 Journal of vascular surgery Vol.67 No.6
<P>Conclusions: In patients with Buerger disease, endovascular treatment achieved technical success in the majority of the cases and was associated with favorable immediate and late clinical outcomes. These findings indicate that endovascular therapy may be considered a first -line treatment option for severe symptomatic patients with Buerger disease.</P>
Byeong-Keuk Kim,Joo Young Yang,오승진,윤세정,전동운,고영국 연세대학교의과대학 2011 Yonsei medical journal Vol.52 No.5
Purpose: It is unknown whether cilostazol pretreatment reduces postprocedural myonecrosis (PPMN). Cilostazol pretreatment reduces PPMN after percutaneous coronary intervention (PCI). Materials and Methods: A total of 120 patients with stable angina scheduled for elective PCI were randomly assigned to a 7-day pretreatment with Cilostazol (200 mg/day) or to a control group. Creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) levels were measured at baseline and at 6 and 24 hours after PCI. The primary end-point was the occurrence of PPMN, defined as any CK-MB elevation above the upper normal limit (UNL). Aspirin and clopidogrel were co-administered for 7 days before PCI, and resistance to these agents was then assayed using the VerifyNow System. Results: There was no difference in baseline characteristics between the final analyzable cilostazol (n=54) and the control group (n=56). Despite a significantly greater % inhibition of clopidogrel in the cilostazol group (39±23% versus 25±22%, p=0.003), the incidence of PPMN was similar between the cilostazol group (24%) and the control group (25%, p=1.000). The rate of CK-MB elevation at ≥3 times UNL was also similar between the two groups (6% versus 5%, p=0.583). The incidence of cTnI increase over the UNL or to 3 times the UNL was not different between the two groups. There was no significant difference in terms of the rate of adverse events during follow-up, although the cilostazol group showed a tendency to have a slightly higher incidence of entry site hematoma. Conclusion: This trial demonstrated that adjunctive cilostazol pretreatment might not significantly reduce PPMN after elective PCI in patients with stable angina.
Kim, Byeong-Keuk,Kim, Jung-Sun,Ko, Young-Guk,Choi, Donghoon,Jang, Yangsoo,Hong, Myeong-Ki Kluwer Academic Publishers 2012 INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING Vol.28 No.6
<P>Minimal data have been published on the correlation between angiographic late loss (LL) and incomplete neointimal coverage of struts after drug-eluting stent (DES) implantation. Therefore, we evaluated the relationship between angiographic LL and the percentage of uncovered struts on follow-up optical coherence tomography (OCT) images, in all cross-sections of the lesions. From the OCT registry database, 219 lesions without restenosis after DES implantation were divided into tertiles based on angiographic LL: tertile I (LL 0.26 mm), tertile II (0.26 < LL < 0.59 mm), and tertile III (0.59 mm). Lesions with the percentage of uncovered struts in the highest quartile (75th percentile; >6.0%) were defined as highly uncovered; in an independent analysis, lesions without any uncovered strut(s) were defined as completely covered. Higher percentages of uncovered struts were observed in tertile I than in both tertile II and III (10.3 12.8% vs. 4.2 7.4% vs. 2.4 5.1%, respectively; P < 0.001 for I vs. II and I vs. III). Angiographic LL correlated significantly with the percentage of uncovered struts on OCT (r = -0.340, P < 0.001). The best cut-off values of angiographic LL to predict highly uncovered and completely covered lesions were 0.29 mm (area under curves [AUC] = 0.723, P < 0.001) and 0.61 mm (AUC = 0.692, P < 0.001), respectively. Angiographic LL inversely and significantly correlated with the percentage of uncovered struts on OCT after DES implantation.</P>
Kim, Byeong-Keuk,Kim, Jung-Sun,Oh, Changmyung,Ko, Young-Guk,Choi, Donghoon,Jang, Yangsoo,Hong, Myeong-Ki Foundation for Advances in Medicine and Science [e 2011 Clinical cardiology Vol.34 No.2
<P>There are no sufficient data to evaluate the relationship between high-sensitivity C-reactive protein (hs-CRP) and uncovered stent struts on optical coherence tomography (OCT) after drug-eluting stent (DES) implantation.</P>
Kim, Gwang-Sil,Kim, Byeong-Keuk,Shin, Dong-Ho,Kim, Jung-Sun,Hong, Myeong-Ki,Gwon, Hyeon-Cheol,Kim, Hyo-Soo,Yu, Cheol Woong,Park, Hun Sik,Chae, In-Ho,Rha, Seung-Woon,Jang, Yangsoo Wolters Kluwer Health, Inc. All rights reserved. 2017 Coronary artery disease Vol.28 No.5
<P>Conclusion Clinical parameters such as age, diabetes, and heart failure were independent predictors of the composite of cardiac death, myocardial infarction, and stent thrombosis, whereas angiographic or procedural parameters such as lesion length and number of implanted stents were predictors of target-vessel revascularization. Clinical outcomes after CTO intervention were worse in patients with multiple risk factors. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.</P>
Statin and clinical outcomes of primary prevention in individuals aged >75 years: The SCOPE-75 study
Kim, Kyu,Lee, Chan Joo,Shim, Chi-Young,Kim, Jung-Sun,Kim, Byeong-Keuk,Park, Sungha,Chang, Hyuk-Jae,Hong, Geu-Ru,Ko, Young-Guk,Kang, Seok-Min,Choi, Donghoon,Ha, Jong-Won,Hong, Myeong-Ki,Jang, Yangsoo,L Elsevier Scientific Publ. Co 2019 Atherosclerosis Vol.284 No.-
<P><B>Abstract</B></P> <P><B>Background and aims</B></P> <P>Limited data is available on the benefit of statin for primary prevention in the elderly. The aim of this study is to investigate whether statin for primary prevention is effective in lowering the cardiovascular risk and all-cause death in individuals aged >75 years.</P> <P><B>Methods</B></P> <P>This was a retrospective, propensity score-matched study and data were acquired between 2005 and 2016 in a tertiary university hospital. Of the 6414 patients screened, 1559 statin-naïve patients without a history of atherosclerotic cardiovascular disease before the index visit were included. After propensity score matching, 1278 patients (639 statin users, 639 statin non-users) were finally analyzed. Primary outcome variables included major adverse cardiovascular and cerebrovascular events (MACCE) and all-cause death. MACCE included cardiovascular death, nonfatal myocardial infarction, coronary revascularization, and nonfatal stroke or transient ischemic attack.</P> <P><B>Results</B></P> <P>At a median follow-up of 5.2 years, statin users had lower rates of MACCE (2.15 <I>vs.</I> 1.25 events/100 person-years; hazard ratio, 0.59; <I>p</I> = 0.005) and all-cause death (1.19 <I>vs.</I> 0.65 events/100 person-years; hazard ratio, 0.56; <I>p</I> = 0.02), as well as lower levels of low-density lipoprotein-cholesterol than did non-users. The Kaplan-Meier curves revealed lower event rates in statin users (hazard ratio: 0.59 for MACCE and 0.56 for all-cause death). The incidence of myocardial infarction and coronary revascularization were lower in statin users.</P> <P><B>Conclusions</B></P> <P>Statin therapy for primary prevention was clearly associated with lower risk of cardiovascular events and all-cause death in individuals aged >75 years. These results support more active statin use in this population.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Effect of statins for primary prevention was analyzed in individuals aged >75 years. </LI> <LI> Statin was associated with lower cardiovascular risk and all-cause death. </LI> <LI> Rates of MI and coronary revascularization were lower in statin users. </LI> <LI> These results support a more active statin use in this population. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Kim, Byung Gyu,Ko, Young-Guk,Hong, Sung-Jin,Ahn, Chul-Min,Kim, Jung-Sun,Kim, Byeong-Keuk,Choi, Donghoon,Jang, Yangsoo,Hong, Myeong-Ki,Lee, Seung Hyun,Lee, Sak,Chang, Byung-Chul Elsevier 2018 INTERNATIONAL JOURNAL OF CARDIOLOGY Vol.255 No.-
<P><B>Abstract</B></P> <P><B>Aims</B></P> <P>Peripheral artery disease (PAD) is frequently present in patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis. This study assessed the impact of PAD on clinical outcome after TAVI.</P> <P><B>Methods</B></P> <P>A total of 115 patients who underwent TAVI were evaluated retrospectively. Patients were divided into PAD and non-PAD groups, with PAD defined as stenosis≥50% in lower extremity arteries. Immediate and late clinical outcomes were compared between the two groups.</P> <P><B>Results</B></P> <P>PAD was present in 31.3% (36/115) of the patients undergoing TAVI. Compared to the non-PAD group, the PAD group had higher Society of Thoracic Surgeons' (STS) risk scores (8.83%±6.20% vs 6.23%±4.15%, p=0.039) and more frequent diagnoses of diabetes (52.8% vs 30.4%, p=0.021) and multi-vessel coronary artery disease (55.6% vs 29.1%, p=0.007). The PAD group also had higher incidence of major vascular complication (11.1% vs 1.3%, p=0.033), 30-day mortality (13.9% vs 1.3%, p<0.001), and subsequent 1-year (30.6% vs 3.8%, p<0.001) and 2-year (47.2% vs. 10.1%, p<0.001) all-cause mortality. PAD was identified as an independent predictor of increased 1-year mortality (hazard ratio [HR] 8.65; 95% confidence interval [CI], 1.05–71.14, p=0.045) after TAVI along with high STS score (HR 11.18, 95% CI 1.36–92.04, p=0.025).</P> <P><B>Conclusions</B></P> <P>Presence of PAD was significantly associated with increased rates of major vascular complications as well as immediate and late mortality in patients undergoing TAVI. Assessment of PAD before TAVI is essential to choose an access strategy and to predict clinical results.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Peripheral Artery Disease is common in transcatheter aortic valve implant patients. </LI> <LI> PAD was associated with major vascular complications in TAVI patients (p=0.033). </LI> <LI> PAD was associated with immediate and late mortality in TAVI patients (p<0.001). </LI> <LI> PAD was an independent predictor of 1-year mortality after TAVI (p=0.025). </LI> <LI> Assessment of PAD before TAVI is essential to determine procedure and clinical outcome. </LI> </UL> </P>